Reviewed by the OrganaBio scientific team.
Parkinson’s disease (PD) is increasingly understood as a neuro-immune disease in which peripheral immune activation precedes and amplifies CNS neurodegeneration. Peripheral blood PBMCs from PD donors carry the α-synuclein-reactive T cells, activated monocyte profiles, and NK cell changes that reflect systemic immune involvement in PD pathology. For researchers developing immunomodulatory therapies, α-synuclein-targeted antibodies, and gut-brain axis interventions in PD, disease-state PBMCs provide the peripheral immune correlates needed for assay development and pharmacodynamic testing.
PD Immunology: The Peripheral Component
α-Synuclein aggregates (Lewy bodies and Lewy neurites) are the pathological hallmark of PD. Misfolded α-synuclein acts as a DAMP (danger-associated molecular pattern), activating monocytes and macrophages through TLR2 signaling and driving inflammasome activation. CD4+ and CD8+ T cells reactive to α-synuclein epitopes are found in PD peripheral blood and are the primary evidence for an adaptive immune contribution to dopaminergic neuron loss. These α-synuclein-reactive T cells are MHC-restricted and clonally expanded, meeting criteria for antigen-specific autoimmunity. The gut-brain axis in PD (α-synuclein pathology beginning in the enteric nervous system) is reflected in altered mucosal immune populations in PD peripheral blood.
OrganaBio Parkinson’s Donor Catalog
| Attribute | Available |
|---|---|
| PD subtype | Idiopathic PD; LRRK2, GBA mutation status on select lots |
| Disease duration / Hoehn and Yahr | Documented on select lots; early vs. late-stage available |
| Medication status | Levodopa, dopamine agonist, MAO-B inhibitor documented |
| Cognitive status | PD without dementia vs. PDD documented where available |
| PBMC format | Cryopreserved; fresh on scheduled collection |
| Lot documentation | CoA, diagnosis, subtype/mutation, Hoehn-Yahr, medications, flow cytometry |
Key Cell Populations for PD Research
- α-Synuclein-reactive T cells (CD4+ and CD8+): Clonally expanded T cells reactive to α-synuclein epitopes detected in PD peripheral blood using HLA-peptide tetramers; MHC class I and II restricted; primary evidence for adaptive autoimmunity in PD
- Classical monocytes: TLR2-activated by misfolded α-synuclein; IL-6, TNF-α, and NLRP3 inflammasome activation; peripheral monocyte activation mirrors microglial activation in the substantia nigra
- CD4+ T cells (Th1/Th17 imbalance): IFN-γ and IL-17A producing T cells elevated in PD; neurotoxic through microglial activation amplification; neuroprotective Th2 and Treg subsets relatively depleted
- Regulatory T cells: Reduced and functionally impaired in PD; inversely correlated with UPDRS motor score in some cohort studies; Treg enhancement is an active neuroprotective strategy
- NK cells: Altered cytotoxicity in PD; GBA mutation carriers show more pronounced NK cell functional changes; innate immune surveillance changes measurable in peripheral blood
Research Applications
- α-Synuclein T cell reactivity assays: HLA-peptide tetramer staining and ELISPOT-based detection of α-synuclein-reactive T cells in PD PBMCs
- TLR2/NLRP3 inflammasome activation: monocyte stimulation with recombinant misfolded α-synuclein for innate immune pathway characterization
- LRRK2 inhibitor immune pharmacodynamics: LRRK2 is expressed in monocytes and T cells; LRRK2 inhibitors have immunomodulatory effects measurable in PD PBMCs
- Anti-α-synuclein antibody pharmacodynamics: passive immunization effects on α-synuclein handling in monocyte and T cell assays
- Gut-brain axis immune profiling: mucosal T cell populations and α4β7+ gut-homing cells in PD peripheral blood
- GBA mutation-stratified immune phenotyping: GBA-PD has stronger inflammatory phenotype than idiopathic PD; comparative NK cell and monocyte assays

